Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGFR1/VEGFR2 peptide vaccine in refractory breast cancer
NCT00677326Phase 2Terminated
- Sponsor
- The University of Tokyo
- Start
- May 2008
- Primary completion
- Apr 2009
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LY6K + VEGFR1 + VEGFR2, elpamitide in breast cancer, sponsored by The University of Tokyo. Started May 2008; status: terminated.
02
Drugs
LY6K + VEGFR1 + VEGFR2elpamitide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00677326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00677326.